NO944933L - Fremgangsmåte for å inhibere sykdomstilstander i brystet - Google Patents

Fremgangsmåte for å inhibere sykdomstilstander i brystet

Info

Publication number
NO944933L
NO944933L NO944933A NO944933A NO944933L NO 944933 L NO944933 L NO 944933L NO 944933 A NO944933 A NO 944933A NO 944933 A NO944933 A NO 944933A NO 944933 L NO944933 L NO 944933L
Authority
NO
Norway
Prior art keywords
breast
disease states
procedure
inhibiting disease
inhibiting
Prior art date
Application number
NO944933A
Other languages
English (en)
Other versions
NO944933D0 (no
Inventor
James Joseph Sales
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944933D0 publication Critical patent/NO944933D0/no
Publication of NO944933L publication Critical patent/NO944933L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å Inhibere sykdomstilstander l brystet ved administrering til et menneske som har b ehov for behandling av en effektiv mengde av en forbindelse med formelen OCH2CH2¿R1 (D hvor R1 og R3 uavhengig av hverandre er hydrogen, - O O fc alkyl ) , eller -C-Ar, hvor Ar er eventuelt substituert f enyl ; R2 er valgt fra gruppen bestående av pyrrolidln, heksametylenamlno og plperldlno; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO944933A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere sykdomstilstander i brystet NO944933L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,955 US5593987A (en) 1993-12-21 1993-12-21 Methods of inhibiting breast disorders

Publications (2)

Publication Number Publication Date
NO944933D0 NO944933D0 (no) 1994-12-19
NO944933L true NO944933L (no) 1995-06-22

Family

ID=22625779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944933A NO944933L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere sykdomstilstander i brystet

Country Status (15)

Country Link
US (1) US5593987A (no)
EP (1) EP0659419A1 (no)
JP (1) JPH07196501A (no)
KR (1) KR950016729A (no)
CN (1) CN1108100A (no)
AU (1) AU701701B2 (no)
CA (1) CA2138501A1 (no)
CZ (1) CZ321294A3 (no)
HU (1) HUT71480A (no)
IL (1) IL112039A (no)
NO (1) NO944933L (no)
NZ (1) NZ270170A (no)
PH (1) PH31326A (no)
RU (1) RU2126251C1 (no)
ZA (1) ZA9410088B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CA2372720C (en) 1999-05-04 2007-09-11 John Antony Kanis Androgen glycosides and androgenic activity thereof
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001242A (en) * 1974-08-02 1977-01-04 Eli Lilly And Company D-6-methyl-8-formyl-10α-alkoxy-8-ergolene
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5227375A (en) * 1990-02-08 1993-07-13 Endorecherche, Inc. Aromatase inhibitors
FR2677027B1 (fr) * 1991-05-27 1993-09-10 Roussel Uclaf Nouveaux produits sterouides substitues en position 6, et comportant, en position 10, un radical thioethyle, leur procede de preparation leurs intermediaires, leur application comme medicaments.
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CA2138501A1 (en) 1995-06-22
HU9403666D0 (en) 1995-02-28
IL112039A (en) 1999-03-12
KR950016729A (ko) 1995-07-20
ZA9410088B (en) 1996-06-19
AU8156094A (en) 1995-06-29
AU701701B2 (en) 1999-02-04
PH31326A (en) 1998-07-06
IL112039A0 (en) 1995-03-15
NZ270170A (en) 1997-07-27
CN1108100A (zh) 1995-09-13
NO944933D0 (no) 1994-12-19
US5593987A (en) 1997-01-14
HUT71480A (en) 1995-11-28
RU2126251C1 (ru) 1999-02-20
JPH07196501A (ja) 1995-08-01
RU94045280A (ru) 1996-10-10
EP0659419A1 (en) 1995-06-28
CZ321294A3 (en) 1995-08-16

Similar Documents

Publication Publication Date Title
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
DK0664126T3 (da) Hæmning af trombin
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin